Browse by UCL people
Group by: Type | Date
Number of items: 91.
Article
Abbosh, Christopher;
Frankell, Alexander M;
Harrison, Thomas;
Kisistok, Judit;
Garnett, Aaron;
Johnson, Laura;
Veeriah, Selvaraju;
... Swanton, Charles; + view all
(2023)
Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA.
Nature
, 616
(7957)
pp. 553-562.
10.1038/s41586-023-05776-4.
|
|
Abbosh, C;
Birkbak, NJ;
Wilson, GA;
Jamal-Hanjani, M;
Constantin, T;
Salari, R;
Le Quesne, J;
... Dessimoz, C; + view all
(2017)
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.
Nature
, 545
pp. 446-451.
10.1038/nature22364.
|
|
AbdulJabbar, K;
Raza, SEA;
Rosenthal, R;
Jamal-Hanjani, M;
Veeriah, S;
Akarca, A;
Lund, T;
... Yuan, Y; + view all
(2020)
Geospatial immune variability illuminates differential evolution of lung adenocarcinoma.
Nature Medicine
, 26
pp. 1054-1062.
10.1038/s41591-020-0900-x.
|
|
Al Bakir, Maise;
Huebner, Ariana;
Martínez-Ruiz, Carlos;
Grigoriadis, Kristiana;
Watkins, Thomas BK;
Pich, Oriol;
Moore, David A;
... Swanton, Charles; + view all
(2023)
The evolution of non-small cell lung cancer metastases in TRACERx.
Nature
10.1038/s41586-023-05729-x.
(In press).
|
|
Alrifai, D;
Forster, MD;
Janes, SM;
(2018)
Emerging resistance pathways in lung cancer: what has ROS-1 taught us?
[Editorial comment].
Translational Lung Cancer Research
, 7
(Suppl 1)
S9-S12.
10.21037/tlcr.2017.11.13.
|
 |
|
Arkenau, H-T;
Italiano, A;
Mak, G;
Toulmonde, M;
Baird, RD;
Garcia-Corbacho, J;
Plummer, R;
... Spicer, J; + view all
(2018)
An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours.
European Journal of Cancer
, 103
pp. 17-23.
10.1016/j.ejca.2018.07.134.
|
|
Au, L;
Hatipoglu, E;
Robert de Massy, M;
Litchfield, K;
Beattie, G;
Rowan, A;
Schnidrig, D;
... TRACERx Renal Consortium; + view all
(2021)
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma.
Cancer Cell
, 39
pp. 1497-1518.
10.1016/j.ccell.2021.10.001.
|
|
|
Barber, Paul R;
Mustapha, Rami;
Flores-Borja, Fabian;
Alfano, Giovanna;
Ng, Kenrick;
Weitsman, Gregory;
Dolcetti, Luigi;
... Ng, Tony; + view all
(2022)
Predicting progression-free survival after systemic therapy in advanced head and neck cancer: Bayesian regression and model development.
eLife
, 11
, Article e73288. 10.7554/eLife.73288.
|
|
Bentham, R;
Litchfield, K;
Watkins, TBK;
Lim, EL;
Rosenthal, R;
Martinez-Ruiz, C;
Hiley, CT;
... McGranahan, N; + view all
(2021)
Using DNA sequencing data to quantify T cell fraction and therapy response.
Nature
, 597
pp. 555-560.
10.1038/s41586-021-03894-5.
|
|
Brown, Sarah R;
Hinsley, Samantha;
Hall, Emma;
Hurt, Chris;
Baird, Richard D;
Forster, Martin;
Scarsbrook, Andrew F;
(2022)
A Road Map for Designing Phase I Clinical Trials of Radiotherapy–Novel Agent Combinations.
Clinical Cancer Research
, 28
(17)
pp. 3639-3651.
10.1158/1078-0432.CCR-21-4087.
|
|
Byers, LA;
Navarro, A;
Schaefer, E;
Johnson, M;
Özgüroğlu, M;
Han, J-Y;
Bondarenko, I;
... Forster, M; + view all
(2021)
A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer.
Clinical Lung Cancer
, 22
(6)
pp. 531-540.
10.1016/j.cllc.2021.04.005.
|
|
|
Calvo, E;
Moreno, V;
Flynn, M;
Holgado, E;
Olmedo, ME;
Criado, MPL;
Kahatt, C;
... Forster, M; + view all
(2017)
Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study.
Annals of Oncology
, 28
(10)
pp. 2559-2566.
10.1093/annonc/mdx357.
|
|
|
Capper, D;
Engel, NW;
Stichel, D;
Lechner, M;
Gloess, S;
Schmid, S;
Koelsche, C;
... Schueller, U; + view all
(2018)
DNA methylation-based reclassification of olfactory neuroblastoma.
Acta Neuropathologica
, 136
(2)
pp. 255-271.
10.1007/s00401-018-1854-7.
|
|
Chambers, P;
Wei, L;
Forster, MD;
Kipps, E;
Wong, ICK;
Jani, Y;
(2021)
Evidence to guide the optimal timing for pre-chemotherapy blood tests for early breast, colorectal cancer and diffuse large B-cell lymphoma.
Cancer Medicine
10.1002/cam4.4316.
(In press).
|
|
|
Chambers, P;
Jani, Y;
Wei, L;
Kipps, E;
Forster, MD;
Wong, ICK;
(2019)
Patient Factors and their Impact on Neutropenic Events: A Systematic review and meta-analysis.
Supportive Care in Cancer
, 27
(7)
pp. 2413-2424.
10.1007/s00520-019-04773-6.
|
|
Chambers, P;
Man, KKC;
Lui, VWY;
Mpima, S;
Nasuti, P;
Forster, MD;
Wong, ICK;
(2020)
Understanding Molecular Testing Uptake Across Tumor Types in Eight Countries: Results From a Multinational Cross-Sectional Survey.
JCO Precision Oncology
, 16
(8)
e770-e778.
10.1200/JOP.19.00507.
|
|
Conibear, J;
Chia, B;
Ngai, Y;
Bates, AT;
Counsell, N;
Patel, R;
Eaton, D;
... Landau, D; + view all
(2018)
Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer.
BMJ Open
, 8
(4)
, Article e020690. 10.1136/bmjopen-2017-020690.
|
|
|
Crolley, VE;
Hanna, D;
Joharatnam-Hogan, N;
Chopra, N;
Bamac, E;
Desai, M;
Lam, YC;
... Khan, K; + view all
(2020)
COVID-19 in cancer patients on systemic anti-cancer therapies: outcomes from the CAPITOL (COVID-19 Cancer PatIenT Outcomes in North London) cohort study.
Therapeutic Advances in Medical Oncology
, 12
pp. 1-14.
10.1177/1758835920971147.
|
|
|
de Bono, JS;
Concin, N;
Hong, DS;
Thistlethwaite, FC;
Machiels, J-P;
Arkenau, H-T;
Plummer, R;
... Lassen, U; + view all
(2019)
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.
Lancet Oncology
, 20
(3)
pp. 383-393.
10.1016/S1470-2045(18)30859-3.
|
|
Diamond, JR;
Goff, B;
Forster, MD;
Bendell, JC;
Britten, CD;
Gordon, MS;
Gabra, H;
... Moore, KM; + view all
(2017)
Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers.
Investigational New Drugs
, 35
(5)
pp. 627-633.
10.1007/s10637-017-0444-1.
|
|
Dikaios, N;
Atkinson, D;
Tudisca, C;
Purpura, P;
Forster, M;
Ahmed, H;
Beale, T;
... Punwani, S; + view all
(2017)
A comparison of Bayesian and non-linear regression methods for robust estimation of pharmacokinetics in DCE-MRI and how it affects cancer diagnosis.
Computerized Medical Imaging and Graphics
, 56
pp. 1-10.
10.1016/j.compmedimag.2017.01.003.
|
|
Dikaios, N;
Punwani, S;
Hamy, V;
Purpura, P;
Rice, S;
Forster, M;
Mendes, R;
... Atkinson, D; + view all
(2013)
Noise Estimation from Averaged Diffusion Weighted Images: Can Unbiased Quantitative Decay Parameters Assist Cancer Evaluation?
Magnetic Resonance in Medicine
, 71
(6)
pp. 2105-2117.
10.1002/mrm.24877.
|
|
|
Dillon, Magnus T;
Guevara, Jeane;
Mohammed, Kabir;
Patin, Emmanuel C;
Smith, Simon A;
Dean, Emma;
Jones, Gemma N;
... Harrington, Kevin J; + view all
(2024)
Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation.
Journal of Clinical Investigation
, 134
(2)
, Article e175369. 10.1172/JCI175369.
|
|
Dillon, MT;
Boylan, Z;
Smith, D;
Guevara, J;
Mohammed, K;
Peckitt, C;
Saunders, M;
... Harrington, KJ; + view all
(2018)
PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours.
Clinical and Translational Radiation Oncology
, 12
pp. 16-20.
10.1016/j.ctro.2018.06.001.
|
|
|
Dillon, MT;
Grove, L;
Newbold, KL;
Shaw, H;
Brown, NF;
Mendell, J;
Chen, S;
... Harrington, KJ; + view all
(2019)
Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study.
Clinical Cancer Research
, 25
(2)
pp. 487-495.
10.1158/1078-0432.CCR-18-1539.
|
|
Fennell, D;
Danson, S;
Woll, P;
Forster, M;
Talbot, D;
Child, J;
Farrelly, L;
... Wheeler, G; + view all
(2020)
Ganetespib in combination with pemetrexed-platinum chemotherapy in patients with pleural Mesothelioma (MESO-02): A phase Ib trial.
Clinical Cancer Research
, 26
(18)
pp. 4748-4755.
10.1158/1078-0432.CCR-20-1306.
|
|
Forster, Martin;
Brana, Irene;
Lopez Pousa, Antonio;
Doger, Bernard;
Roxburgh, Patricia;
Bajaj, Pawan;
Peguero, Julio;
... Triebel, Frederic; + view all
(2024)
Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell Carcinoma.
Clinical Cancer Research
, 30
(17)
pp. 3726-3734.
10.1158/1078-0432.CCR-24-0473.
|
|
Forster, M;
Hackshaw, A;
De Pas, T;
Cobo, M;
Garrido, P;
Summers, Y;
Dingemans, AMC;
... Lee, SM; + view all
(2018)
A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3).
Lung Cancer
, 120
pp. 27-33.
10.1016/j.lungcan.2018.03.007.
|
|
|
Forster, MD;
Devlin, M-J;
(2018)
Immune Checkpoint Inhibition in Head and Neck Cancer.
Frontiers in Oncology
, 8
, Article 310. 10.3389/fonc.2018.00310.
|
|
|
Forster, MD;
Dillon, MT;
Kocsis, J;
Remenár, É;
Pajkos, G;
Rolland, F;
Greenberg, J;
(2019)
Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study.
European Journal of Cancer
, 123
pp. 36-47.
10.1016/j.ejca.2019.08.017.
|
|
|
Forster, MD;
Moschetta, M;
Uccello, M;
Kasenda, B;
Mak, G;
McClelland, A;
Boussios, S;
(2017)
Dynamics of neutrophils to lymphocyte ratio (NLR) predict outcomes of PD-1/PD-L1 blockade.
BioMed Research International
, 2017
, Article 1506824. 10.1155/2017/1506824.
|
|
|
Foy, V;
Schenk, MW;
Baker, K;
Gomes, F;
Lallo, A;
Frese, KK;
Forster, M;
... Blackhall, F; + view all
(2017)
Targeting DNA damage in SCLC.
[Review].
Lung Cancer
, 114
pp. 12-22.
10.1016/j.lungcan.2017.10.006.
|
|
Frankell, Alexander M;
Dietzen, Michelle;
Al Bakir, Maise;
Lim, Emilia L;
Karasaki, Takahiro;
Ward, Sophia;
Veeriah, Selvaraju;
... Swanton, Charles; + view all
(2024)
The evolution of lung cancer and impact of subclonal selection in TRACERx (vol 616, pg 525, 2023).
[Corrigendum].
Nature
, 631
, Article E15. 10.1038/s41586-024-07738-w.
|
|
|
Frankell, AM;
Dietzen, M;
Al Bakir, M;
Lim, EL;
Karasaki, T;
Ward, S;
Veeriah, S;
... Gilbert, K; + view all
(2023)
The evolution of lung cancer and impact of subclonal selection in TRACERx.
Nature
, 616
pp. 525-533.
10.1038/s41586-023-05783-5.
|
|
Harrington, KJ;
Bhide, SA;
Forster, MD;
Good, JS;
Gunn, L;
Kong, A;
Melcher, AA;
... Wong, KH; + view all
(2020)
Looking a Gift Horse in the Mouth: Observations on NHS England's Interim Guidance on Pembrolizumab in Head and Neck Squamous Cell Cancer.
Clinical Oncology
, 32
(8)
pp. 490-492.
10.1016/j.clon.2020.05.016.
|
|
|
Herbst, RS;
Garon, EB;
Kim, D-W;
Cho, BC;
Perez-Gracia, JL;
Han, J-Y;
Arvis, CD;
... Baas, P; + view all
(2020)
Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1Positive, Advanced NonSmall-Cell Lung Cancer in the KEYNOTE-010 Study.
Journal of Clinical Oncology
, 38
(14)
pp. 1580-1590.
10.1200/JCO.19.02446.
|
|
Hobor, S;
Al Bakir, M;
Hiley, CT;
Skrzypski, M;
Frankell, AM;
Bakker, B;
Watkins, TBK;
... Clipson, A; + view all
(2024)
Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling.
Nature Communications
, 15
, Article 4871. 10.1038/s41467-024-47606-9.
|
|
Hong, DS;
Concin, N;
Vergote, I;
de Bono, JS;
Slomovitz, BM;
Drew, Y;
Arkenau, H-T;
... Coleman, RL; + view all
(2020)
Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer.
Clinical Cancer Research
, 26
(6)
pp. 1220-1228.
10.1158/1078-0432.CCR-19-2962.
|
|
Hopper, C;
Jerjes, W;
Sultan, A;
Forster, M;
carnell, D;
Simeon, C;
Berg, K;
... Hamdoon, Z; + view all
(2016)
Disulfonated tetraphenyl chlorin (TPCS2a)–induced photochemical internalisation of bleomycin in patients with solid malignancies: A first-in-man phase I dose escalation clinical trial.
The Lancet Oncology
, 17
(9)
pp. 1217-1229.
10.1016/S1470-2045(16)30224-8.
|
|
Jamal-Hanjani, M;
Wilson, GA;
McGranahan, N;
Birkbak, NJ;
Watkins, TBK;
Veeriah, S;
Shafi, S;
... Swanton, C; + view all
(2017)
Tracking the Evolution of Non-Small-Cell Lung Cancer.
New England Journal of Medicine
, 376
(22)
pp. 2109-2121.
10.1056/NEJMoa1616288.
|
|
Jamieson, L;
Forster, MD;
Zaki, K;
Mitra, S;
Alli, H;
O’Connor, A;
Patel, A;
... Chambers, PC; + view all
(2020)
Immunotherapy and associated immune-related adverse events at a large UK centre: a mixed methods study.
BMC Cancer
, 20
, Article 743. 10.1186/s12885-020-07215-3.
|
|
|
Janku, Filip;
Choong, Grace M;
Opyrchal, Mateusz;
Dowlati, Afshin;
Hierro, Cinta;
Rodon, Jordi;
Wicki, Andreas;
... Adjei, Alex A; + view all
(2024)
A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors.
Cancers
, 16
(6)
, Article 1137. 10.3390/cancers16061137.
|
|
Joshi, K;
Robert de Massy, M;
Ismail, M;
Reading, JL;
Uddin, I;
Woolston, A;
Hatipoglu, E;
... Chain, B; + view all
(2019)
Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer.
Nature Medicine
, 25
pp. 1549-1559.
10.1038/s41591-019-0592-2.
|
|
Jurmeister, Philipp;
Glöß, Stefanie;
Roller, Renée;
Leitheiser, Maximilian;
Schmid, Simone;
Mochmann, Liliana H;
Payá Capilla, Emma;
... Capper, David; + view all
(2022)
DNA methylation-based classification of sinonasal tumors.
Nature Communications
, 13
(1)
, Article 7148. 10.1038/s41467-022-34815-3.
|
|
Karamchandani, Searan;
Sahovaler, Axel;
Crosbie-Jones, Elizabeth;
McGurk, Mark;
Thavaraj, Selvam;
Alibhai, Mustansir;
Wan, Simon;
... Schilling, Clare; + view all
(2024)
Incidence and predictive factors for positive non-sentinel lymph nodes in completion neck dissection following a positive sentinel node biopsy in early oral cancer.
Oral Oncology
, 159
, Article 107081. 10.1016/j.oraloncology.2024.107081.
|
|
Kong, A;
Good, J;
Kirkham, A;
Savage, J;
Mant, R;
Llewellyn, L;
Parish, J;
... Mehanna, H; + view all
(2020)
Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the WISTERIA trial protocol.
BMJ Open
, 10
(3)
, Article e033009. 10.1136/bmjopen-2019-033009.
|
|
|
Kristeleit, R;
Moreno, V;
Boni, V;
Guerra, EM;
Kahatt, C;
Romero, I;
Calvo, E;
... Forster, M; + view all
(2021)
Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: Results from an expanded phase i study.
International Journal of Gynecological Cancer
, 31
(11)
pp. 1428-1436.
10.1136/ijgc-2021-002881.
|
|
Kristeleit, R;
Evans, J;
Molife, LR;
Tunariu, N;
Shaw, H;
Slater, S;
Haris, NRM;
... Lopez, J; + view all
(2020)
Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours.
British Journal of Cancer
10.1038/s41416-020-1010-8.
(In press).
|
|
|
Lai, AG;
Pasea, L;
Banerjee, A;
Hall, G;
Denaxas, S;
Chang, WH;
Katsoulis, M;
... Hemingway, H; + view all
(2020)
Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study.
BMJ Open
, 10
(11)
, Article e043828. 10.1136/bmjopen-2020-043828.
|
|
|
Lechner, M;
Chakravarthy, AR;
Walter, V;
Masterson, L;
Feber, A;
Jay, A;
Weinberger, PM;
... Fenton, TR; + view all
(2018)
Frequent HPV-independent p16/INK4A overexpression in head and neck cancer.
Oral Oncology
, 83
pp. 32-37.
10.1016/j.oraloncology.2018.06.006.
|
|
Lechner, M;
Frampton, G;
Fenton, T;
Feber, A;
Palmer, G;
Jay, A;
Pillay, N;
... Boshoff, C; + view all
(2013)
Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumors.
Genome Medicine
, 5
, Article 49. 10.1186/gm453.
|
 |
|
Lechner, M;
Schartinger, VH;
Steele, CD;
Nei, WL;
Ooft, ML;
Schreiber, L-M;
Pipinikas, CP;
... Lund, VJ; + view all
(2021)
Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy.
Nature Communications
, 12
(1)
, Article 117. 10.1038/s41467-020-20308-8.
|
|
|
Lee, SM;
Falzon, M;
Blackhall, F;
Spicer, J;
Nicolson, M;
Chaudhuri, A;
Middleton, G;
... Hackshaw, A; + view all
(2016)
Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET).
Journal of Clinical Oncology
, 35
(4)
pp. 402-411.
10.1200/JCO.2016.68.1841.
|
|
|
Lindsay, CR;
Shaw, EC;
Moore, DA;
Rassl, D;
Jamal-Hanjani, M;
Steele, N;
Naheed, S;
... Kerr, KM; + view all
(2021)
Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists.
British Journal of Cancer
10.1038/s41416-021-01407-9.
(In press).
|
|
|
Lindsay, CR;
Jamal-Hanjani, M;
Forster, M;
Blackhall, F;
(2018)
KRAS: Reasons for optimism in lung cancer.
European Journal of Cancer
, 99
pp. 20-27.
10.1016/j.ejca.2018.05.001.
|
|
Litchfield, K;
Stanislaw, S;
Spain, L;
Gallegos, LL;
Rowan, A;
Schnidrig, D;
Rosenbaum, H;
... Turajlic, S; + view all
(2020)
Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue.
Cell Reports
, 31
(5)
p. 107550.
10.1016/j.celrep.2020.107550.
|
|
Liu, Jacklyn;
Sutton, Liam;
Rehman, Umar;
Rodriguez-Justo, Manuel;
Jay, Amrita;
Forster, Martin;
Beale, Tim;
... Lechner, Matt; + view all
(2025)
Squamous Cell Carcinoma of the Mastoid Cavity in a Patient with Lynch Syndrome - A New Lynch Syndrome-Associated Cancer and Its Clinical Implications.
European Archives of Oto-Rhino-Laryngology
10.1007/s00405-025-09429-2.
(In press).
|
|
López, S;
Lim, EL;
Horswell, S;
Haase, K;
Huebner, A;
Dietzen, M;
Mourikis, TP;
... McGranahan, N; + view all
(2020)
Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution.
Nature Genetics
, 52
(3)
pp. 283-293.
10.1038/s41588-020-0584-7.
|
|
McGranahan, N;
Rosenthal, R;
Hiley, CT;
Rowan, AJ;
Watkins, TBK;
Wilson, GA;
Birkbak, NJ;
... Swanton, C; + view all
(2017)
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution.
Cell
10.1016/j.cell.2017.10.001.
(In press).
|
|
|
Mehanna, Hisham;
Gaunt, Piers;
Kong, Anthony;
Hartley, Andrew;
Sanghera, Paul;
Forster, Martin;
Sen, Mehmet;
... Nankivell, Paul; + view all
(2024)
CompARE: study protocol for a phase III randomised controlled platform trial comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer.
Trials
, 25
(1)
, Article 50. 10.1186/s13063-023-07881-1.
|
|
Mehanna, H;
Rischin, D;
Wong, SJ;
Gregoire, V;
Ferris, R;
Waldron, J;
Le, Q-T;
... Porceddu, S; + view all
(2020)
De-Escalation After DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup Framework for Future De-Escalation Studies.
Journal of Clinical Oncology
, 38
(22)
pp. 2552-2557.
10.1200/JCO.20.00056.
|
|
|
Middleton, G;
Fletcher, P;
Popat, S;
Savage, J;
Summers, Y;
Greystoke, A;
Gilligan, D;
... Billingham, L; + view all
(2020)
The National Lung Matrix Trial of personalized therapy in lung cancer.
Nature
, 583
(7818)
pp. 807-812.
10.1038/s41586-020-2481-8.
|
|
Miller, RE;
Brown, NE;
Speirs, A;
Shaw, HM;
Adeleke, S;
Gougis, P;
Bennett, P;
... Kristeleit, RS; + view all
(2016)
The use of next generation sequencing (NGS) to guide patient selection for phase 1 clinical trials.
Annals of Oncology
, 27
(Suppl 6)
pp. 114-135.
10.1093/annonc/mdw368.44.
|
|
Moore, DA;
Benafif, S;
Poskitt, B;
Argue, S;
Lee, SM;
Ahmad, T;
Papadatos-Pastos, D;
... Forster, MD; + view all
(2021)
Optimising fusion detection through sequential DNA and RNA molecular profiling of non-small cell lung cancer.
Lung Cancer
, 161
pp. 55-59.
10.1016/j.lungcan.2021.08.008.
|
|
Moore, DA;
Kushnir, M;
Mak, G;
Winter, H;
Curiel, T;
Voskoboynik, M;
Moschetta, M;
... Arkenau, HT; + view all
(2019)
Prospective analysis of 895 patients on a UK Genomics Review Board.
ESMO Open
, 4
(2)
, Article e000469. 10.1136/esmoopen-2018-000469.
|
|
|
Ng, Kenrick;
Metcalf, Rob;
Sacco, Joseph;
Kong, Anthony;
Wheeler, Graham;
Forsyth, Sharon;
Bhat, Reshma;
... Forster, Martin; + view all
(2023)
Protocol for the EACH trial: a multicentre phase II study evaluating the safety and antitumour activity of the combination of avelumab, an anti-PD-L1 agent, and cetuximab, as any line treatment for patients with recurrent/metastatic head and neck squamous cell cancer (HNSCC) in the UK.
BMJ Open
, 13
(11)
, Article e070391. 10.1136/bmjopen-2022-070391.
|
|
Olmedo, ME;
Forster, M;
Moreno, V;
Lopez-Criado, MP;
Brana, I;
Flynn, M;
Doger, B;
... Calvo, E; + view all
(2021)
Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study.
Investigational New Drugs
10.1007/s10637-020-01025-x.
(In press).
|
|
|
Papoutsaki, M-V;
Sidhu, HS;
Dikaios, N;
Singh, S;
Atkinson, D;
Kanber, B;
Beale, T;
... Punwani, S; + view all
(2021)
Utility of diffusion MRI characteristics of cervical lymph nodes as disease classifier between patients with head and neck squamous cell carcinoma and healthy volunteers.
NMR in Biomedicine
, Article e4587. 10.1002/nbm.4587.
(In press).
|
|
|
Patel, P;
Alrifai, D;
McDonald, F;
Forster, M;
(2020)
Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited).
British Journal of Cancer
, 123
pp. 18-27.
10.1038/s41416-020-01071-5.
|
|
|
Paz-Ares, L;
Forster, M;
Boni, V;
Szyldergemajn, S;
Corral, J;
Turnbull, S;
Cubillo, A;
... Calvo, E; + view all
(2017)
Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors.
Investigational New Drugs
, 35
(2)
pp. 198-206.
10.1007/s10637-016-0410-3.
|
|
Pruis, Melinda A;
Krebs, Matthew G;
Plummer, Ruth;
De Vos, Filip;
Angevin, Eric;
Prenen, Hans;
Forster, Martin D;
... Lolkema, Martijn P; + view all
(2023)
A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer.
The Oncologist
, Article oyad146. 10.1093/oncolo/oyad146.
(In press).
|
|
Puglisi, M;
Molife, LR;
de Jonge, MJ;
Khan, KH;
Doorn, LV;
Forster, MD;
Blanco, M;
... Eskens, FA; + view all
(2021)
A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors.
Future Oncology
10.2217/fon-2021-0140.
(In press).
|
|
|
Puttick, Clare;
Jones, Thomas P;
Leung, Michelle M;
Galvez-Cancino, Felipe;
Liu, Jiali;
Varas-Godoy, Manuel;
Rowan, Andrew;
... Mcgranahan, Nicholas; + view all
(2024)
MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolution.
Nature Genetics
, 56
(10)
pp. 2121-2131.
10.1038/s41588-024-01883-8.
|
|
|
Rosenthal, R;
Cadieux, EL;
Salgado, R;
Bakir, MA;
Moore, DA;
Hiley, CT;
Lund, T;
... TRACERx consortium; + view all
(2019)
Neoantigen-directed immune escape in lung cancer evolution.
Nature
10.1038/s41586-019-1032-7.
(In press).
|
|
Sacher, Adrian;
LoRusso, Patricia;
Patel, Manish R;
Miller, Wilson H;
Garralda, Elena;
Forster, Martin D;
Santoro, Armando;
... GO42144 Investigator and Study Group; + view all
(2023)
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.
New England Journal of Medicine
, 389
(8)
pp. 710-721.
10.1056/NEJMoa2303810.
|
|
Sage, E;
Davies, A;
Kolluri, K;
Patrick, S;
Weil, B;
Rego, RVTP;
Edwards, A;
... Janes, SM; + view all
(2018)
Targeted stem cells expressing TRAIL as a therapy for lung Cancer TACTICAL: a phase I/II trial.
Lung Cancer
, 115
(Supp. 1)
S87-S87.
10.1016/S0169-5002(18)30222-8.
|
|
Saraswathula, A;
Ullah, MN;
Liu, J;
Takahashi, Y;
Mahajan, A;
Battocchio, S;
Bossi, P;
... London, NR; + view all
(2025)
International, Multi-Institutional Evaluation of Practice Patterns and Outcomes for Recurrent and Metastatic Sinonasal Undifferentiated Carcinoma.
Journal of Neurological Surgery Part B: Skull Base
, 86
(5)
pp. 538-546.
10.1055/s-0044-1791573.
|
|
Sharma, RA;
Plummer, R;
Stock, JK;
Greenhalgh, TA;
Ataman, O;
Kelly, S;
Clay, R;
... Wedge, SR; + view all
(2016)
Clinical development of new drug-radiotherapy combinations.
NATURE REVIEWS CLINICAL ONCOLOGY
, 13
(10)
pp. 627-642.
10.1038/nrclinonc.2016.79.
|
|
|
Turri-Zanoni, M;
Dalfino, G;
Lechner, M;
Dallan, I;
Battaglia, P;
Facco, C;
Franzi, F;
... Castelnuovo, P; + view all
(2022)
Biphenotypic sinonasal sarcoma: European multicentre case-series and systematic literature review.
Acta Otorhinolaryngologica Italica
, 42
(6)
pp. 545-553.
10.14639/0392-100X-N2087.
|
|
Vargas, FA;
Furness, AJS;
Litchfield, K;
Joshi, K;
Rosenthal, R;
Ghorani, E;
Solomon, I;
... Quezada, SA; + view all
(2018)
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.
Cancer Cell
, 33
(4)
pp. 649-663.
10.1016/j.ccell.2018.02.010.
|
|
|
Vargas, FA;
Furness, AJS;
Solomon, I;
Joshi, K;
Mekkaoui, L;
Lesko, MH;
Rota, EM;
... Quezada, SA; + view all
(2017)
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.
Immunity
, 46
(4)
pp. 577-586.
10.1016/j.immuni.2017.03.013.
|
|
|
Walker, K;
Hinsley, S;
Phillip, R;
Oughton, JB;
Murden, G;
Chalmers, AJ;
Faivre-Finn, C;
... Young, R; + view all
(2022)
Implementation of the Time-to-Event Continuous Reassessment Method Design in a Phase I Platform Trial Testing Novel Radiotherapy-Drug Combinations-CONCORDE.
JCO Precision Oncology
, 6
(6)
, Article e2200133. 10.1200/PO.22.00133.
|
|
Walls, GM;
Oughton, JB;
Chalmers, AJ;
Brown, S;
Collinson, F;
Forster, MD;
Franks, KN;
... Greystoke, A; + view all
(2020)
CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer.
Clinical and Translational Radiation Oncology
, 25
pp. 61-66.
10.1016/j.ctro.2020.09.006.
|
|
Conference item
|
Dillon, MT;
Espinasse, A;
Ellis, S;
Mohammed, K;
Grove, LG;
McLellan, L;
Smith, SA;
... Harrington, KJ; + view all
(2017)
A Phase I dose-escalation study of ATR inhibitor monotherapy with AZD6738 in advanced solid tumors (PATRIOT Part A).
Presented at: Annual Meeting of the American-Association-for-Cancer-Research (AACR), Washington, DC.
|
|
|
Kristeleit, RS;
Miller, R;
Sellers, L;
Brown, N;
Devlin, M;
Woo, K;
Boyd, A;
... Linch, M; + view all
(2017)
A first-in-human Phase I/II, dose escalation, pharmacokinetic study to assess safety and tolerability of VAL201 in advanced prostate cancer.
Presented at: 15th International Congress on Targeted Anticancer Therapies (TAT 2017), Paris, France.
|
|
Miller, RE;
Devlin, M;
Brown, N;
Woo, K;
Grunewald, T;
Speirs, A;
Mitchison, M;
... Kristeleit, R; + view all
(2017)
Guidance by molecular selection improves the outcome of early phase treatment for gynecological (GYN) cancers.
Presented at: AACR Annual Meeting 2017, Washington, D.C., USA.
|
|
Papoutsaki, M;
Sidhu, H;
Dikaios, N;
Atkinson, D;
Beale, T;
Morley, S;
Forster, M;
... Punwani, S; + view all
(2018)
Pre-treatment intra- and inter- voxel magnetic resonance diffusion heterogeneity correlates with chemoradiotherapy treatment outcome of patients with head and neck squamous cell carcinoma.
Presented at: Joint Annual Meeting ISMRM-ESMRMB 2018, Paris, France.
(In press).
|
Poster
|
Dillon, M;
Ellis, S;
Grove, L;
McLellan, L;
Clack, G;
Smith, S;
Laude, J;
... Harrington, K; + view all
(2016)
PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours.
Presented at: ASCO 2016 Annual Meeting: Poster Session, Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics, Chicago.
|
|
Forster, M;
Mendes, R;
Harrington, K;
Guerrero-Urbano, T;
Baines, H;
Spanswick, V;
Ensell, L;
... Beare, S; + view all
(2016)
A phase I study of olaparib in addition to cisplatin-based concurrent chemoradiotherapy for patients with high risk locally advanced squamous cell carcinoma of the head and neck (HNSCC).
Presented at: 2016 ASCO Annual Meeting, Chicago, IL, USA.
|
|
Harrington, K;
Forster, M;
Dillon, M;
Grove, L;
Adeleke, S;
Chen, S;
Diamond, J;
... Greenberg, J; + view all
(2016)
Patritumab or Placebo Plus Cetuximab and Platinum-Based Therapy in Squamous Cell Carcinoma of the Head and Neck (SCCHN): a Phase 2 Study.
Presented at: ASCO 2016 Annual Meeting: Poster Session, Head and Neck Cancer, Chicago.
|
|
Miller, R;
Devlin, M-J;
Brown, NF;
Grunewald, T;
McCormack, M;
Lockley, M;
Ledermann, JA;
... Kristeleit, RS; + view all
(2017)
Outcome of patients with advanced endometrial and cervical cancer treated in a phase 1 unit.
Presented at: 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL, USA.
|
|
